BioSpace News Archive

Allyx Therapeutics today disclosed its plans to present the Phase 1 single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) meeting in Boston on October 27, 2023.

Sight Sciences, Inc. announced they will be hosting a TearCare SAHARA Six Month RCT Results reception in San Francisco, CA on Friday, November 3, 2023 from 5:00 to 7:00 pm PT.

Capricor Therapeutics announced that the Company will host a webinar with the nonprofit organization Parent Project Muscular Dystrophy to review key regulatory details and provide clinical updates that support the advancement of its ongoing HOPE-3, Phase 3 clinical trial of CAP-1002 for treating Duchenne muscular dystrophy.

Amgen announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday, Oct. 24, 2023.

Apollo Medical Holdings, Inc. announced that it will release financial results for the third quarter ended September 30, 2023, after the close of the stock market on Tuesday, November 7, 2023.

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Thursday, November 2, 2023 to discuss its third quarter 2023 operating results.

Invitae, a leading medical genetics company, announced the appointment of veteran healthcare leader David Sholehvar, M.D., as chief operating officer, effective November 13, 2023.

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the second quarter ended September 30, 2023, after the close of market on Thursday, October 26, 2023.

NLS Pharmaceutics Ltd. announced that it will postpone the company update previously scheduled for Friday, October 20, 2023, due to important developments impacting the timing of the event.

Arcutis Biotherapeutics, Inc. announced the commencement of an underwritten public offering of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.